Andrew N Schiff
CIK 1172252 · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LOXO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
APT. 4
NEW YORK, NY 10011
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GLUE | Director | — | $10.48 | — | $0 | 6 | 2026-06-12 |
| ACRS | Director | 459,995 | $3.79 | $1.74M | -$1.15M | 19 | 2026-06-08 |
| Elevation Oncology, Inc. (ELEV) Delisted | — | $0.36 | — | $0 | 1 | 2021-06-28 | |
| Zosano Pharma Corp (ZSAN) Delisted | 10%+ Owner | 77,664 | $0.56 | $43.3K | $0 | 2 | 2019-12-06 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 288,571 | $18.62 | $5.37M | $7.50M | 1 | 2019-07-15 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | Director | 0 | — | — | -$35.35M | 11 | 2017-05-01 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | — | $1.51 | — | $0 | 1 | 2015-06-10 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 3,452,493 | — | — | $37.59M | 1 | 2014-08-06 |
| INTERPHARM HOLDINGS INC (IPA) Delisted | 10%+ Owner | — | $2.07 | — | $0 | 1 | 2008-03-03 |
Recent Filings · Page 5 of 5
44 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-10-23 | — | Buy (P) | +2,470,590 | $21.00M | |
| 2013-06-20 | Zeltiq Aesthetics Inc (ZLTQ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-18 | Zeltiq Aesthetics Inc (ZLTQ) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-03-03 | INTERPHARM HOLDINGS INC (IPA) Delisted | Other (J) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.